Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, July 20, 2022
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
[ Wed, Jul 20th 2022
] - WOPRAI
Yigal Nochomovitz Downgraded (ATRA) to Strong Sell and Held Target at $75 on, Jul 20th, 2022
Yigal Nochomovitz of Citigroup, Downgraded "Atara Biotherapeutics, Inc." (ATRA) to Strong Sell and Held Target at $75 on, Jul 20th, 2022.
Yigal has made no other calls on ATRA in the last 4 months.
There are 4 other peers that have a rating on ATRA. Out of the 4 peers that are also analyzing ATRA, 2 agree with Yigal's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Anupam Rama of "JP Morgan" Downgraded from Buy to Hold and Held Target at $250 on, Wednesday, July 13th, 2022
- Benjamin Burnett of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $125 on, Wednesday, July 13th, 2022
These are the ratings of the 2 analyists that currently disagree with Yigal
- Salveen Richter of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $100 on, Tuesday, May 24th, 2022
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $725 on, Monday, May 23rd, 2022
